Chronic opioid use after laryngeal cancer treatment.
chronic use
head and neck cancer
laryngeal carcinoma
larynx cancer
opioid
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
14
11
2020
received:
01
02
2020
accepted:
17
12
2020
pubmed:
29
12
2020
medline:
1
7
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
Survivors of head and neck cancer may be at increased risk for chronic opioid use and questions remain about risk factors. Retrospective study of patients with laryngeal cancer prescribed opioids utilizing the Truven Health Marketscan database. Patients had laryngeal cancer, underwent treatment, filled an opioid prescription, and were enrolled in this private insurance plan 1 year prior to and after treatment. In this study, 7484 patients were included; 17.2% developed chronic opioid use, defined as consecutive opioid fills at least 90 days after treatment cessation. Early opioid use (OR = 3.607, 95% CI [3.125-4.163]), tobacco use (OR = 1.28, 95% CI [1.117-1.467]), median morphine milligram equivalent (MME; OR = 1.001, 95% CI [1.000-1.0001]), and radiation alone (OR = 1.435, 95% CI [1.199-1.717]) were predictive of chronic opioid use. Nearly one in five patients prescribed opioids during treatment developed chronic use. Providers should discuss the risk of chronic opioid use, set expectations for opioid weaning, and consider adjunct pain regimens to develop effective pain management strategies.
Sections du résumé
BACKGROUND
Survivors of head and neck cancer may be at increased risk for chronic opioid use and questions remain about risk factors.
METHODS
Retrospective study of patients with laryngeal cancer prescribed opioids utilizing the Truven Health Marketscan database. Patients had laryngeal cancer, underwent treatment, filled an opioid prescription, and were enrolled in this private insurance plan 1 year prior to and after treatment.
RESULTS
In this study, 7484 patients were included; 17.2% developed chronic opioid use, defined as consecutive opioid fills at least 90 days after treatment cessation. Early opioid use (OR = 3.607, 95% CI [3.125-4.163]), tobacco use (OR = 1.28, 95% CI [1.117-1.467]), median morphine milligram equivalent (MME; OR = 1.001, 95% CI [1.000-1.0001]), and radiation alone (OR = 1.435, 95% CI [1.199-1.717]) were predictive of chronic opioid use.
CONCLUSIONS
Nearly one in five patients prescribed opioids during treatment developed chronic use. Providers should discuss the risk of chronic opioid use, set expectations for opioid weaning, and consider adjunct pain regimens to develop effective pain management strategies.
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1242-1251Subventions
Organisme : NIH National Center for Advancing Translational Sciences
ID : UL1TR001998
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Arianpour K, Nguyen B, Yuhan B, Svider PF, Eloy JA, Folbe AJ. Opioid prescription among sinus surgeons. Am J Rhinol Allergy. 2018;32:1945892418773578.
Cramer JD, Wisler B, Gouveia CJ. Opioid stewardship in otolaryngology: state of the art review. Otolaryngol Head Neck Surg. 2018;158(5):817-827.
Schwartz MA, Naples JG, Kuo CL, Falcone TE. Opioid prescribing patterns among otolaryngologists. Otolaryngol Head Neck Surg. 2018;158(5):854-859.
Svider PF, Arianpour K, Guo E, et al. Opioid prescribing patterns among otolaryngologists: crucial insights among the medicare population. Laryngoscope. 2018;128:1576-1581.
Patel S, Sturm A, Bobian M, Svider PF, Zuliani G, Kridel R. Opioid use by patients after rhinoplasty. JAMA Facial Plast Surg. 2018;20(1):24-30.
Sethi RKV, Panth N, Puram SV, Varvares MA. Opioid prescription patterns among patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2018;144(4):382-383.
McGrath PA. Development of the World Health Organization guidelines on cancer pain relief and palliative care in children. J Pain Symptom Manage. 1996;12(2):87-92.
Portenoy RK. Treatment of cancer pain. Lancet. 2011;377(9784):2236-2247.
Buchakjian MR, Davis AB, Sciegienka SJ, Pagedar NA, Sperry SM. Longitudinal perioperative pain assessment in head and neck cancer surgery. Ann Otol Rhinol Laryngol. 2017;126(9):646-653.
Alfieri S, Ripamonti CI, Marceglia S, et al. Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer. Head Neck. 2016;38(Suppl 1):E1521-E1527.
Daeninck PJ, Bruera E. Opioid use in cancer pain. Is a more liberal approach enhancing toxicity? Acta Anaesthesiol Scand. 1999;43(9):924-938.
Kwon JH, Hui D, Chisholm G, Bruera E. Predictors of long-term opioid treatment among patients who receive chemoradiation for head and neck cancer. Oncologist. 2013;18(6):768-774.
Mercadante S. Opioid responsiveness in patients with advanced head and neck cancer. Support Care Cancer. 1998;6(5):482-485.
Pang J, Tringale KR, Tapia VJ, et al. Opioid prescribing practices in patients undergoing surgery for oral cavity cancer. Laryngoscope. 2018;128:2361-2366.
Jarlbaek L, Hansen DG, Bruera E, Andersen M. Frequency of opioid use in a population of cancer patients during the trajectory of the disease. Clin Oncol (R Coll Radiol). 2010;22(3):199-207.
Chua KS, Reddy SK, Lee MC, Patt RB. Pain and loss of function in head and neck cancer survivors. J Pain Symptom Manage. 1999;18(3):193-202.
Cramer JD, Johnson JT, Nilsen ML. Pain in head and neck cancer survivors: prevalence, predictors, and quality-of-life impact. Otolaryngol Head Neck Surg. 2018;159:194599818783964.
Webster LR. Risk factors for opioid-use disorder and overdose. Anesth Analg. 2017;125(5):1741-1748.
Saraswathula A, Chen MM, Mudumbai SC, Whittemore AS, Divi V. Persistent postoperative opioid use in older head and neck cancer patients. Otolaryngol Head Neck Surg. 2018;160:194599818778276.
Lee JS, Hu HM, Edelman AL, et al. New persistent opioid use among patients with cancer after curative-intent surgery. J Clin Oncol. 2017;35(36):4042-4049.
Centers for Disease Control and Prevention. Commercial insurance claims at a glance. https://www.cdc.gov/visionhealth/vehss/data/claims/marketscan.html. Accessed July 5, 2020.
Centers for Disease Control and Prevention. Analyzing opioid prescription data and oral morphine milligram equivalents (MME). https://www.cdc.gov/drugoverdose/resources/data.html. Accessed January 26, 2019.
Inacio MC, Hansen C, Pratt NL, Graves SE, Roughead EE. Risk factors for persistent and new chronic opioid use in patients undergoing total hip arthroplasty: a retrospective cohort study. BMJ Open. 2016;6(4):e010664.
National Cancer Institute: Divison of Cancer Control & Population Sciences. NCI comorbidity index overview. https://healthcaredelivery.cancer.gov/seermedicare/considerations/comorbidity.html. Accessed September 3, 2020.
Miller J, Ulrich R. The quest for an optimal alpha. PLoS One. 2019;14(1):e0208631.
Carmichael AN, Morgan L, Del Fabbro E. Identifying and assessing the risk of opioid abuse in patients with cancer: an integrative review. Subst Abuse Rehabil. 2016;7:71-79.
Shuman AG, Terrell JE, Light E, et al. Predictors of pain among patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2012;138(12):1147-1154.
Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use - United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66(10):265-269.
Craker NC, Gal TJ, Wells L, Schadler A, Pruden S, Aouad RK. Chronic opioid use after laryngeal cancer treatment: a VA study. Otolaryngol Head Neck Surg. 2020;162(4):492-4927.
Karvonen-Gutierrez CA, Ronis DL, Fowler KE, Terrell JE, Gruber SB, Duffy SA. Quality of life scores predict survival among patients with head and neck cancer. J Clin Oncol. 2008;26(16):2754-2760.
Trotter PB, Norton LA, Loo AS, et al. Pharmacological and other interventions for head and neck cancer pain: a systematic review. J Oral Maxillofac Res. 2013;3(4):e1.
Kataoka T, Kiyota N, Shimada T, et al. Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. Auris Nasus Larynx. 2016;43(6):677-684.
Lalla RV, Choquette LE, Curley KF, et al. Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncol. 2014;50(11):1098-1103.
Clayburgh D, Stott W, Bolognone R, et al. A randomized controlled trial of corticosteroids for pain after transoral robotic surgery. Laryngoscope. 2017;127(11):2558-2564.
Carpenter PS, Shepherd HM, McCrary H, et al. Association of celecoxib use with decreased opioid requirements after head and neck cancer surgery with free tissue reconstruction. JAMA Otolaryngol Head Neck Surg. 2018;144(11):988-994.
McDermott JD, Eguchi M, Stokes WA, et al. Short- and long-term opioid use in patients with oral and oropharynx cancer. Otolaryngol Head Neck Surg. 2019;160(3):409-419.